Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 65, Issue 11, 2013, Pages 2791-2802

  Blits, Marjolein ^a   Jansen, Gerrit ^a   Assaraf, Yehuda G ^b   Van De Wiel, Mark A ^a   Lems, Willem F ^a   Nurmohamed, Mike T ^a   Van Schaardenburg, Dirkjan ^a   Voskuyl, Alexandre E ^a   Wolbink, Gert Jan ^c   Vosslamber, Saskia ^a   Verweij, Cornelis L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Jan Van Breemen Research Institute/Reade   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C2; ABC TRANSPORTER C5; DIHYDROFOLATE REDUCTASE; GAMMA GLUTAMYL HYDROLASE; METHOTREXATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLATE METABOLISM; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ENZYMES; FEMALE; FOLATE RECEPTOR 1; FOLATE RECEPTOR 2; FOLIC ACID; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROTON-COUPLED FOLATE TRANSPORTER; REDUCED FOLATE CARRIER PROTEIN; TRANSCRIPTOME; UP-REGULATION;

EID: 84886801040     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38094     Document Type: Article

References (50)

1. Scott DL, Wolfe F, Huizinga TW,. Rheumatoid arthritis. Lancet 2010; 376: 1094-108.
2. McInnes IB, Schett G,. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
3. Kremer JM,. Toward a better understanding of methotrexate. Arthritis Rheum 2004; 50: 1370-82.
4. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P,. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-74.
5. Gonen N, Assaraf YG,. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 2012; 15: 183-210.
6. Bertino JR,. Karnofsky memorial lecture: ode to methotrexate. J Clin Oncol 1993; 11: 5-14.
7. Cronstein BN,. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005; 57: 163-72.
8. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH,. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001; 60: 729-35.
9. Spurlock CF III, Tossberg JT, Fuchs HA, Olsen NJ, Aune TM,. Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum 2012; 64: 1780-9.
10. Phillips DC, Woollard KJ, Griffiths HR,. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 2003; 138: 501-11.
11. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP,. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102: 322-8.
12. Majumdar S, Aggarwal BB,. Methotrexate suppresses NF-κB activation through inhibition of IκBα phosphorylation and degradation. J Immunol 2001; 167: 2911-20.
13. Van der Heijden JW, Dijkmans BA, Scheper RJ, Jansen G,. Drug insight: resistance to methotrexate and other disease-modifying antirheumatic drugs-from bench to bedside. Nat Clin Pract Rheumatol 2007; 3: 26-34.
14. Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006; 127: 917-28.
15. Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara N, Nakamura T, et al. Selective expression of folate receptor β and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 1609-16.
16. Van der Heijden JW, Oerlemans R, Dijkmans BA, Qi H, van der Laken CJ, Lems WF, et al. Folate receptor β as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum 2009; 60: 12-21.
17. Stark M, Wichman C, Avivi I, Assaraf YG,. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood 2009; 113: 4362-9.
18. Rots MG, Pieters R, Peters GJ, Noordhuis P, van Zantwijk CH, Kaspers GJ, et al. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood 1999; 93: 1677-83.
19. Baggott JE, Morgan SL, Vaughn WH,. Differences in methotrexate and 7-hydroxymethotrexate inhibition of folate-dependent enzymes of purine nucleotide biosynthesis. Biochem J 1994; 300: 627-9.
20. Allegra CJ, Drake JC, Jolivet J, Chabner BA,. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A 1985; 82: 4881-5.
21. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999; 59: 2532-5.
22. Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007; 56: 1765-75.
23. Stamp LK, Roberts RL,. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases. Pharmacogenomics 2011; 12: 1449-63.
24. Fransen J, Kooloos WM, Wessels JA, Huizinga TW, Guchelaar HJ, van Riel PL, et al. Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. Pharmacogenomics 2012; 13: 1087-94.
25. Dervieux T, Zablocki R, Kremer J,. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology (Oxford) 2010; 49: 2337-45.
26. Stamp LK, O'Donnell JL, Chapman PT, Zhang M, James J, Frampton C, et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum 2010; 62: 359-68.
27. Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007; 66: 1008-14.
28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
29. Chaussabel D, Pascual V, Banchereau J,. Assessing the human immune system through blood transcriptomics. BMC Biol 2010; 8: 84.
30. Ball CA, Awad IA, Demeter J, Gollub J, Hebert JM, Hernandez-Boussard T, et al. The Stanford Microarray Database accommodates additional microarray platforms and data formats. Nucleic Acids Res 2005; 33: D580-2.
31. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116-21.
32. Batliwalla FM, Baechler EC, Xiao X, Li W, Balasubramanian S, Khalili H, et al. Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun 2005; 6: 388-97.
33. Van Baarsen LG, Wijbrandts CA, Gerlag DM, Rustenburg F, van der Pouw Kraan TC, Dijkmans BA, et al. Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis. Genes Immun 2010; 11: 622-9.
34. Mattson MP, Shea TB,. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003; 26: 137-46.
35. Viswanathan GA, Seto J, Patil S, Nudelman G, Sealfon SC,. Getting started in biological pathway construction and analysis. PLoS Comput Biol 2008; 4: e16.
36. Tibbetts AS, Appling DR,. Compartmentalization of mammalian folate-mediated one-carbon metabolism. Annu Rev Nutr 2010; 30: 57-81.
37. Van der Heijden JW, Oerlemans R, Tak PP, Assaraf YG, Kraan MC, Scheffer GL, et al. Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. Arthritis Rheum 2009; 60: 669-77.
38. Van de Ven R, Oerlemans R, van der Heijden JW, Scheffer GL, de Gruijl TD, Jansen G, et al. ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer. J Leukoc Biol 2009; 86: 1075-87.
39. De Rotte MC, Luime JJ, Bulatovic M, Hazes JM, Wulffraat NM, de Jonge R,. Do snapshot statistics fool us in MTX pharmacogenetic studies in arthritis research? Rheumatology (Oxford) 2010; 49: 1200-1.
40. Owen SA, Hider SL, Martin P, Bruce IN, Barton A, Thomson W,. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J 2013; 13: 227-34.
41. Dalrymple JM, Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Barclay ML,. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 3299-308.
42. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50: 2766-74.
43. Dervieux T, Wessels JA, Kremer JM, Padyukov L, Seddighzadeh M, Saevarsdottir S, et al. Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenet Genomics 2012; 22: 1-9.
44. Burmester GR, Mariette X, Montecucco C, Monteagudo-Saez I, Malaise M, Tzioufas AG, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007; 66: 732-9.
45. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
46. Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH,. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 2009; 36: 1429-41.
47. Walling J,. From methotrexate to pemetrexed and beyond: a review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 2006; 24: 37-77.
48. Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosokowsky A, Forsch RA, et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 1995; 48: 459-71.
49. Nagayoshi R, Nakamura M, Ijiri K, Yoshida H, Komiya S, Matsuyama T,. LY309887, antifolate via the folate receptor suppresses murine type II collagen-induced arthritis. Clin Exp Rheumatol 2003; 21: 719-25.
50. Jansen G, Mauritz R, Kathmann I, Boritzki TJ, Peters GJ,. Membrane transport properties and biological activity of stereo-isomers of glycinamide ribonucleotide formyltransferase (GARTF) inhibitors AG2032 and AG2034. Pteridines 2010; 20: 109-14.